王 黎,馬 琦,房彬彬,朱 筠,王淑霞,張朝霞,姚 華
?
·論著·
葡萄糖激酶調(diào)節(jié)蛋白基因rs1260326多態(tài)性與新疆維吾爾族人群2型糖尿病的相關(guān)性研究
王 黎,馬 琦,房彬彬,朱 筠,王淑霞,張朝霞,姚 華
目的 探討葡萄糖激酶調(diào)節(jié)蛋白(GCKR)基因rs1260326多態(tài)性與新疆維吾爾族2型糖尿病(T2DM)的關(guān)系。方法 選取2012年6月—2013年3月新疆醫(yī)科大學(xué)第一附屬醫(yī)院確診為T2DM的維吾爾族患者1 000例為T2DM組,同期選取該院的體檢健康者1 008例為對照組。收集所有受試者身高、體質(zhì)量、臀圍、腰圍(WC)、收縮壓(SBP)、舒張壓(DBP)等一般臨床資料,計算體質(zhì)指數(shù)(BMI)、腰臀比(WHR)。檢測并比較其生化指標(biāo)〔總膽固醇(TC)、三酰甘油(TG)、高密度脂蛋白膽固醇(HDL-C)、低密度脂蛋白膽固醇(LDL-C)、空腹血糖(FPG)〕。采用Sequenom Mass ARRAY系統(tǒng)對GCKR基因rs1260326位點進(jìn)行基因分型,比較T2DM組和對照組GCKR基因rs1260326位點基因型分布及等位基因頻率差異;采用Logistic回歸分析GCKR基因rs1260326多態(tài)性與T2DM的關(guān)系。結(jié)果 T2DM組BMI、WHR、WC高于對照組(P<0.05);兩組SBP、DBP比較,差異無統(tǒng)計學(xué)意義(P>0.05)。T2DM組TC、FPG高于對照組,HDL-C、LDL-C低于對照組(P<0.05);兩組TG比較,差異無統(tǒng)計學(xué)意義(P>0.05)。兩組GCKR基因rs1260326位點基因型分布均符合Hardy-Weinberg遺傳平衡定律(P>0.05),說明兩組樣本具有群體代表性。T2DM組與對照組rs1260326位點基因型分布、rs1260326位點等位基因頻率比較,差異無統(tǒng)計學(xué)意義(P>0.05)。Logistic回歸分析結(jié)果表明,GCKR基因rs1260326隱性遺傳模式是T2DM的影響因素(P<0.05)。多因素Logistic回歸分析結(jié)果顯示,入選主效應(yīng)模型的變量有性別、WHR、TC、TG、HDL-C、GCKR基因rs1260326隱性遺傳模式(P<0.05)。結(jié)論 在新疆維吾爾族中,GCKR基因rs1260326多態(tài)性與T2DM相關(guān),TT基因型可能是新疆維吾爾族人群T2DM發(fā)生的保護(hù)因素。
糖尿病,2型;多態(tài)性,單核苷酸;葡萄糖激酶調(diào)節(jié)蛋白基因;維吾爾族
王黎,馬琦,房彬彬,等.葡萄糖激酶調(diào)節(jié)蛋白基因rs1260326多態(tài)性與新疆維吾爾族人群2型糖尿病的相關(guān)性研究[J].中國全科醫(yī)學(xué),2015,18(21):2511-2515.[www.chinagp.net]
Wang L,Ma Q,Fang BB,et al.Relationship between the polymorphism of GCKR gene rs1260326 and type 2 diabetes in Uygur in Xinjiang[J].Chinese General Practice,2015,18(21):2511-2515.
2型糖尿病(T2DM)以胰島β細(xì)胞功能受損和/或外周胰島素抵抗導(dǎo)致體內(nèi)血糖水平升高為特點,是遺傳與環(huán)境共同作用的結(jié)果[1]。T2DM是目前致死和致殘的主要疾病之一,調(diào)查顯示,其患病率在中國人群中呈上升趨勢,成為嚴(yán)重影響居民身心健康的公共衛(wèi)生問題[2]。葡萄糖激酶(glucokinase,GCK)在調(diào)節(jié)體內(nèi)血糖平衡、肝臟葡萄糖利用率和生產(chǎn)率以及胰島β細(xì)胞分泌胰島素的過程中起著關(guān)鍵作用[3]。葡萄糖激酶調(diào)節(jié)蛋白(glucokinase regulator protein,GCKR)是GCK的限速因子,通過6-磷酸果糖和1-磷酸果糖加強(qiáng)或拮抗對GCK的調(diào)節(jié),從而在保持血糖穩(wěn)態(tài)中起重要作用[4]。全基因組關(guān)聯(lián)分析(genome-wide association study,GWAS)發(fā)現(xiàn),在歐洲、亞洲和非洲人群中GCKR基因多態(tài)性與空腹血糖(FPG)水平相關(guān)[5-7],然而其最小等位基因頻率(MAF)在不同人群中存在差異,具有種族異質(zhì)性[8]。研究表明,GCKR基因rs1260326與降低FPG水平、增加胰島β細(xì)胞分泌功能指數(shù)(HOMA-B)以及空腹三酰甘油(TG)水平相關(guān)[9]。新疆維吾爾族人群T2DM的患病率(23.81%)遠(yuǎn)高于漢族人群(13.59%)[10],該人群T2DM患者合并血脂紊亂、肥胖、代謝綜合征較漢族人群多。而維吾爾族人群GCKR基因多態(tài)性與T2DM的關(guān)系國內(nèi)外尚無研究。本研究以新疆維吾爾族人群為研究對象,檢測GCKR基因rs1260326位點基因型分布和等位基因頻率,并探討其與T2DM的關(guān)系。
1.1 研究對象 選取2012年6月—2013年3月新疆醫(yī)科大學(xué)第一附屬醫(yī)院確診為T2DM的維吾爾族患者1 000例為T2DM組,其中男627例,女373例;年齡20~83歲,平均年齡(51.1±9.7)歲。T2DM患者符合
研究背景:
目前對葡萄糖激酶調(diào)節(jié)蛋白(GCKR)基因rs1260326多態(tài)性與2型糖尿病(T2DM)相關(guān)性的研究多數(shù)集中在歐洲白種人和亞洲黃種人,對其他民族研究較少。
《中國2型糖尿病防治指南(2007年版)》公布的T2DM診斷標(biāo)準(zhǔn)[11]:糖尿病癥狀加隨機(jī)血糖≥11.1 mmol/L或FPG≥7.0 mmol/L或既往有確切糖尿病病史、正在使用降糖藥物或胰島素者,并排除1型糖尿病、繼發(fā)性T2DM、嚴(yán)重肝腎功能不全及其他內(nèi)分泌代謝疾病。同期選取該院的體檢健康者1 008例為對照組,其中男633例,女375例;年齡20~83歲,平均年齡(50.4±9.7)歲。體檢健康者經(jīng)仔細(xì)詢問病史和相關(guān)檢查,無糖尿病家族史且糖耐量檢查正常,排除高血壓、內(nèi)分泌疾病、惡性腫瘤、冠心病、慢性肝腎疾病及其他慢性疾病。兩組受試者均是在新疆地區(qū)長期居住的維吾爾族,相互之間沒有血緣關(guān)系。兩組受試者性別、年齡比較,差異均無統(tǒng)計學(xué)意義(χ2=0.002,P=0.964;t′=1.796,P=0.073)。本研究獲得新疆醫(yī)科大學(xué)第一附屬醫(yī)院倫理委員會批準(zhǔn),所有受試者簽署知情同意書。
1.2 標(biāo)本收集、生化檢測及基因組DNA提取 收集所有受試者身高、體質(zhì)量、臀圍、腰圍(WC)、收縮壓(SBP)、舒張壓(DBP)等一般臨床資料,計算體質(zhì)指數(shù)(BMI)、腰臀比(WHR)。所有受試者禁食8 h以上,于次日清晨采集靜脈血5 ml,并分為2份。一份用于生化指標(biāo)的檢測,如總膽固醇(TC)、TG、高密度脂蛋白膽固醇(HDL-C)、低密度脂蛋白膽固醇(LDL-C)、FPG等,均由新疆醫(yī)科大學(xué)第一附屬醫(yī)院檢驗中心統(tǒng)一測定。另一份采用人血基因組提取試劑盒(北京百泰克生物技術(shù)有限公司)提取基因組DNA,置-80 ℃冰箱保存集中送檢。
1.3 基因分型 按照MAF>0.05、連鎖不平衡程度(r2)≥0.8篩選條件,選取rs1260326位點。采用Sequenom Mass ARRAY系統(tǒng)(San Diego,CA,USA)對所有樣本的rs1260326位點進(jìn)行基因分型。隨機(jī)抽取5%的樣本進(jìn)行單核苷酸多態(tài)性(single nucleotide polymorphism,SNP)位點重復(fù)分型檢測,計算基因分型的成功率和一致率,基因分型成功率在95%以上,基因分型一致率在98%以上。
2.1 一般臨床資料比較 T2DM組BMI、WHR、WC高于對照組,差異有統(tǒng)計學(xué)意義(P<0.05)。兩組SBP、DBP比較,差異無統(tǒng)計學(xué)意義(P>0.05,見表1)。
2.2 生化指標(biāo)比較 T2DM組TC、FPG高于對照組,HDL-C、LDL-C低于對照組,差異有統(tǒng)計學(xué)意義(P<0.05)。兩組TG比較,差異無統(tǒng)計學(xué)意義(P>0.05,見表2)。
表1 對照組與T2DM組一般臨床資料比較
Table 1 Comparison of general clinical data between control group and T2DM group
組別例數(shù)BMI(kg/m2)WHR(cm)WC(cm)SBP(mmHg)DBP(mmHg)對照組100027.2±2.40.86±0.0996.2±6.8126±780±5T2DM組100827.5±3.60.93±0.1098.3±10.4127±1679±10t(t')值2.210a-14.8965.436a1.917a-1.423aP值0.027<0.001<0.0010.0550.155
注:a為t′值;T2DM=2型糖尿病,BMI=體質(zhì)指數(shù),WHR=腰臀比,WC=腰圍,SBP=收縮壓,DBP=舒張壓;1 mm Hg=0.133 kPa
Table 2 Comparison of biochemical indicators between control group and T2DM group
組別例數(shù)TCTGHDL-CLDL-CFPG對照組10004.34±1.652.43±2.071.24±0.323.00±0.805.1±1.0T2DM組10084.64±1.262.43±2.000.98±0.312.88±1.349.5±3.4t(t')值4.638a-0.059a-18.580-2.45139.619aP值<0.0010.953<0.0010.014<0.001
注:a為t′值;TC=總膽固醇,TG=三酰甘油,HDL-C=高密度脂蛋白膽固醇,LDL-C=低密度脂蛋白膽固醇,F(xiàn)PG=空腹血糖
本研究價值:
通過本文,可以了解在新疆維吾爾族中,GCKR基因rs1260326多態(tài)性與T2DM相關(guān),TT基因型可能是新疆維吾爾族T2DM發(fā)生的保護(hù)因素。可為新疆地區(qū)維吾爾族人群T2DM的防治提供理論依據(jù)。
2.3 基因分型比較 兩組GCKR基因rs1260326位點基因型分布均符合Hardy-Weinberg遺傳平衡定律(P>0.05),說明兩組樣本具有群體代表性。T2DM組與對照組GCKR基因rs1260326位點基因型分布及等位基因頻率比較,差異均無統(tǒng)計學(xué)意義(P>0.05,見表3)。
2.4 Logistic回歸分析結(jié)果 以是否患T2DM為因變量,GCKR基因rs1260326多態(tài)性為自變量(見表4),進(jìn)行Logistic回歸分析,結(jié)果表明,GCKR基因rs1260326隱性遺傳模式是T2DM的影響因素(P<0.05,見表5)。
表3 對照組與T2DM組GCKR基因rs1260326位點基因分型比較〔n(%)〕
Table 3 Comparison of genotype of GCKR gene rs1260326 locus between control group and T2DM group
組別例數(shù)基因型aCC CT TT等位基因aC T對照組1000369(37.42)433(43.92)184(18.66)1171(59.38)801(40.62)T2DM組1008330(34.37)446(46.46)184(19.17)1106(57.60)814(42.40)χ2值3.7591.266P值0.1530.261
注:a表示有缺失數(shù)據(jù)
表4 T2DM與GCKR基因rs1260326遺傳模式Logistic回歸分析賦值表
Table 4 Assignment table of the Logistic regression analysis of T2DM and GCKR gene rs1260326 genetic model
變量賦值GCKR基因rs1260326相加遺傳模式CC=0,CT=1,TT=2GCKR基因rs1260326顯性遺傳模式CC=0,TT+CT=1GCKR基因rs1260326隱性遺傳模式CC+CT=0,TT=1
注:GCKR=葡萄糖激酶調(diào)節(jié)蛋白
表5 GCKD基因rs1260326遺傳模式對T2DM影響的Logistic回歸分析結(jié)果
Table 5 Results of Logistic regression analysis of the influence of GCKR gene rs1260326 genetic model on T2DM
變量OR值95%CIP值GCKR基因rs1260326相加遺傳模式1.074(0.933,1.236)0.322GCKR基因rs1260326顯性遺傳模式1.275(0.979,1.660)0.072GCKR基因rs1260326隱性遺傳模式0.678(0.477,0.963)0.030
以是否患T2DM為因變量,性別、年齡、BMI、WHR、SBP、DBP、TC、TG、HDL-C、LDL-C和GCKR基因rs1260326隱性遺傳模式為自變量(見表6),進(jìn)行多因素Logistic回歸分析,逐個選入或剔除(前進(jìn)法和后退法)不顯著變量,檢驗水準(zhǔn)取α=0.05,擬合主效應(yīng)模型,結(jié)果顯示,入選主效應(yīng)模型的變量有性別、WHR、TC、TG、HDL-C、GCKR基因rs1260326隱性遺傳模式(P<0.05,見表7)。
表6 T2DM影響因素多因素Logistic回歸分析賦值表
Table 6 Assignment table of multivariate Logistic regression analysis on influencing factors for T2DM
變量賦值性別男=0,女=1年齡(歲)20~=0,30~=1,40~=2,50~=3,60~=4,70~=5BMI(kg/m2)正常(18.5~23.9)=1,超重(24.0~27.9)=2,肥胖(≥28)=3WHR(cm)女≤0.85、男≤0.9=0,女>0.85、男>0.9=1SBP(mmHg)<140=0,≥140=1DBP(mmHg)<90=0,≥90=1TC(mmol/L)<5.18=0,≥5.18=1TG(mmol/L)<1.70=0,≥1.70=1HDL-C(mmol/L)≥1.04=0,<1.04=1LDL-C(mmol/L)<3.37=0,≥3.37=1GCKR基因rs1260326隱性遺傳模式CC+CT=0,TT=1
表7 T2DM影響因素多因素Logistic回歸分析結(jié)果
Table 4 Results of multivariate Logistic regression analysis on influencing factors for T2DM
變量BSEWaldχ2值P值OR值95%CI常數(shù)項0.4570.6870.4420.506--性別0.4520.2283.9490.0471.572(1.006,2.456)年齡0.0490.1120.1860.6661.050(0.842,1.308)BMI0.2430.1412.9730.0851.275(0.967,1.680)WHR1.2420.29417.880<0.0013.462(1.947,6.156)TC1.4130.26528.553<0.0014.110(2.447,6.903)TG-2.3770.26381.380<0.0010.093(0.055,0.156)HDL-C2.4770.226119.924<0.00111.907(7.643,18.550)GCKR基因rs1260326隱性遺傳模式-0.7330.2667.6000.0060.480(0.285,0.809)
GCKR是一種相對分子量為68 kD的不耐熱蛋白質(zhì),是糖異構(gòu)酶家族的成員,定位于染色體2p23,包含19個外顯子和18個內(nèi)含子,全長26 834 bp,編碼625個氨基酸,主要存在于肝臟及胰島細(xì)胞內(nèi)。GCK是糖代謝途徑的第1個關(guān)鍵酶,在調(diào)節(jié)肝細(xì)胞糖代謝和胰島β細(xì)胞分泌胰島素的過程中起著關(guān)鍵作用。GCKR是GCK的限速因子,通過對GCK活性的調(diào)節(jié),促進(jìn)肝臟葡萄糖代謝和調(diào)節(jié)胰島素釋放,在保持機(jī)體血糖穩(wěn)態(tài)過程中起著重要作用[3-4],是T2DM重要的候選基因。rs1260326是GCKR基因的一個SNP位點,定位于GCKR第15個外顯子區(qū)域的446位點,該基因C→T改變能引起氨基酸的替換,從而影響GCKR的表達(dá)及生物活性。研究表明,人類GCKR基因rs1260326多態(tài)性可改變GCK在細(xì)胞內(nèi)的位置,并通過提高高糖環(huán)境下細(xì)胞質(zhì)中GCK的活性,促進(jìn)肝臟葡萄糖的攝取和分解[12]。到目前為止,研究表明,GCKR基因rs1260326位點與超過25種代謝特征相關(guān)[13],其中包括T2DM風(fēng)險[14]、空腹胰島素[15]、TC[16]等,表明這是一個高度多效性的基因。
本研究結(jié)果顯示,T2DM組的BMI、WHR、WC、TC、FPG高于對照組,而HDL-C、LDL-C低于對照組。這與Li等[16]對10 995例生命線隊列和2 438例預(yù)防腎和血管疾病隊列這兩個獨立隊列的研究結(jié)果相符,表明血脂異常與血糖水平升高和胰島素抵抗密切相關(guān),提示T2DM患者合并血脂代謝紊亂,這與T2DM的臨床特點相符合。
本研究結(jié)果顯示,T2DM組與對照組GCKR基因rs1260326位點基因型分布及等位基因頻率無差異。而Logistic回歸分析結(jié)果顯示,GCKR基因rs1260326隱性遺傳模式是T2DM的影響因素,即攜帶CC基因型和攜帶CT基因型的人群比攜帶TT基因型的人群具有更高的患T2DM的危險。多因素Logistic回歸分析發(fā)現(xiàn),在性別、年齡、BMI、WHR、TC、TG、HDL-C不變的情況下,GCKR基因rs1260326隱性遺傳模式仍是T2DM的保護(hù)因素,提示維吾爾族人群GCRK基因rs1260326 TT基因型攜帶者患T2DM的風(fēng)險是CC+CT基因型攜帶者的0.480倍,TT基因型與較低的T2DM風(fēng)險相關(guān)。
Vaxillaire等[17]對4 363例法國人群進(jìn)行GCKR基因rs1260326多態(tài)性與T2DM的流行病學(xué)調(diào)查研究顯示,攜帶CC純合子的人群與攜帶其他雜合子的人群相比,T2DM患病率較高,相反TT型人群患T2DM的風(fēng)險明顯降低。Shen等[18]對阿什米人群GCKR基因多態(tài)性的研究發(fā)現(xiàn),rs1260326 TT基因型人群與其他基因型人群相比,F(xiàn)PG水平較低,TG水平較高。Reiling等[19]對2 361例健康荷蘭白種人與T2DM的相關(guān)性研究表明,GCKR基因rs1260326的C等位基因與FPG水平升高有關(guān)。張曉惠等[20]對甘肅回族T2DM與GCKR基因P446L(rs1260326)基因多態(tài)性的病例對照研究發(fā)現(xiàn),LL基因型在T2DM組和對照組中的分布頻率不同,其GCKR基因LL基因型與增加TG水平、降低FPG水平和降低T2DM的危險性相關(guān)。本研究與上述有關(guān)GCKR基因rs1260326多態(tài)性與T2DM關(guān)系的研究結(jié)果一致,這可能是T等位基因的變異減少了6-磷酸果糖的濃度,使GCKR抑制作用減弱,從而增加GCK活性,改變了GCK在肝臟的調(diào)節(jié)作用,增加了糖酵解,促進(jìn)肝臟糖代謝,提高丙二酰輔酶A的水平,從而降低了T2DM發(fā)病風(fēng)險。
本研究的局限性:T2DM是在遺傳基礎(chǔ)上與環(huán)境因素密切相關(guān)的一種疾病,遺傳因素決定了個體對T2DM的易患性,而多種環(huán)境因素可能是觸發(fā)T2DM的外部原因。本研究未涉及新疆地區(qū)長期居住的其他民族,因此今后將擴(kuò)大新疆地區(qū)其他民族的研究人群進(jìn)行研究。
總之,GCKR基因rs1260326多態(tài)性與新疆維吾爾族T2DM的發(fā)生有關(guān),其TT基因型可降低T2DM的發(fā)病風(fēng)險,成為T2DM的潛在保護(hù)基因。但rs1260326基因變異如何引起胰島素分泌減少,其機(jī)制目前尚不明確,有待進(jìn)一步研究。
[1]Kato N.Insights into the genetic basis of type 2 diabetes[J].J Diabetes Investig,2013,4(3):233-244.
[2]Zheng YY,Fu ZY,Ma YT,et al.Relationship between a novel polymorphism of C5L2 gene C698T and type 2 diabetes in Uygur population of Xinjiang region[J].Chinese Journal of Endocrinology and Metabolism,2012,28(3):186-189.(in Chinese) 鄭穎穎,付真彥,馬依彤,等.C5L2基因新的SNP位點C698T與新疆地區(qū)維吾爾族人群2型糖尿病的相關(guān)性研究[J].中華內(nèi)分泌代謝雜志,2012,28(3):186-189.
[3]Matschinsky FM.Banting Lecture 1995.A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm[J].Diabetes,1996,45(2):223-241.
[4]Chu CA,Fujimoto Y,Igawa K,et al.Rapid translocation of hepatic glucokinase in response to intraduodenal glucose infusion and changes in plasma glucose and insulin in conscious rats[J].Am J Physiol Gastrointest Liver Physiol,2004,286(4):G627-634.
[5]Dupuis J,Langenberg C,Prokopenko I,et al.New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk[J].Nat Genet,2010,42(2):105-116.
[6]Cauchi S,Ezzidi I,El Achhab Y,et al.European genetic variants associated with type 2 diabetes in North African Arabs[J].Diabetes Metab,2012,38(4):316-323.
[7]Takeuchi F,Katsuya T,Chakrewarthy S,et al.Common variants at the GCK,GCKR,G6PC2-ABCB11 and MTNR1B loci are associated with fasting glucose in two Asian populations[J].Diabetologia,2010,53(2):299-308.
[8]Chambers JC,Zhang W,Zabaneh D,et al.Common genetic variation near melatonin receptor MTNR1B contributes to raised plasma glucose and increased risk of type 2 diabetes among Indian Asians and European Caucasians[J].Diabetes,2009,58(11):2703-2708.
[9]Qi Q,Wu Y,Li H,et al.Association of GCKR rs780094,alone or in combination with GCK rs1799884,with type 2 diabetes and related traits in a Han Chinese population[J].Diabetologia,2009,52(5):834-843.
[10]Jiang S,Zhang L,Shao L,et al.Epidemiological investigation and comparison of three different diagnostic criteria regarding metabolic syndrome among population age 30-80 in Xinjiang Uigur areas[J].Chinese Journal of Epidemiology,2011,32(8):756-759.(in Chinese) 蔣升,張莉,邵亮,等.新疆維吾爾族30~80歲人群代謝綜合征調(diào)查及三種診斷標(biāo)準(zhǔn)的對比研究[J].中華流行病學(xué)雜志,2011,32(8):756-759.
[11]中華醫(yī)學(xué)會糖尿病學(xué)分會.中國2型糖尿病防治指南(2007年版)[J].中華醫(yī)學(xué)雜志,2008,88(18):1227-1245.
[12]Rees MG,Wincovitch S,Schultz J,et al.Cellular characterization of the GCKR P446L variant associated with type 2 diabetes risk[J].Diabetologia,2012,55(1):114-122.
[13]Raimondo A,Rees MG,Gloyn AL.Glucokinase regulatory protein:complexity at the crossroads of triglyceride and glucose metabolism[J].Curr Opin Lipidol,2015,26(2):88-95.
[14]Mahendran Y,Vangipurapu J,Cederberg H,et al.Association of ketone body levels with hyperglycemia and type 2 diabetes in 9 398 Finnish men[J].Diabetes,2013,62(10):3618-3626.
[15]Saxena R,Hivert MF,Langenberg C,et al.Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge[J].Nat Genet,2010,42(2):142-148.
[16]Li N,van der Sijde MR,Life Lines Cohort Study Group,et al.Pleiotropic effects of lipid genes on plasma glucose,HbA1c,and HOMA-IR levels[J].Diabetes,2014,63(9):3149-3158.
[17]Vaxillaire M,Cavalcanti-Proenca C,Dechaume A,et al.The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DEDIR prospective general French population[J].Diabetes,2008,57(8):2253-2257.
[18]Shen H,Pollin TI,Damcott CM,et al.Glucokinase regulatory protein gene polymorphism affects postprandial lipemic response in a dietary intervention study[J].Hum Genet,2009,126(4):567-574.
[19]Reiling E,van′t Riet E,Groenewoud MJ,et al.Combined effects of single-nucleotide polymorphisms in GCK,GCKR,G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk[J].Diabetologia,2009,52(9):1866-1870.
[20]Zhang XH,Zhu Z,Liu J,et al.Relationship between glucokinase regulatory protein P446L gene polymorphism and type 2 diabetes mellitus in people of Hui nationality in Gansu province[J].Chinese Journal of Gerontology,2010,30(21):3049-3052.(in Chinese) 張曉惠,朱政,劉靜,等.葡萄糖激酶調(diào)節(jié)蛋白P446L基因多態(tài)性與甘肅回族2型糖尿病的關(guān)系[J].中國老年學(xué)雜志,2010,30(21):3049-3052.
(本文編輯:崔麗紅)
Relationship Between the Polymorphism of GCKR Gene rs1260326 and Type 2 Diabetes in Uygur in Xinjiang
WANGLi,MAQi,FANGBin-bin,etal.
TheKeyLaboratoryofXinjiangMetabolicDisease,theFirstAffiliatedHospitalofXinjiangMedicalUniversity,Urumqi830054,China
Objective To investigate the relationship between the polymorphism of glucokinase regulator(GCKR) gene rs1260326 and type 2 diabetes(T2DM) in Uygur in Xinjiang.Methods 1 000 Uygur patients who were diagnosed with T2DM in the First Affiliated Hospital of Xinjiang Medical University from June 2012 to March 2013 were selected as the T2DM group.Another 1 008 healthy people who received physical examination in the same hospital in the same time period were enrolled as the control group.The general data of the subjects were collected,including height,body mass,hipline,waist circumference(WC),systolic blood pressure(SBP) and diastolic blood pressure(DBP).Then the BMI and WHR of the subjects were calculated.Biochemical indicators were also tested and compared,including TC,TG,HDL-C,LDL-C and FPG.Sequenom Mass ARRAY system was employed to conduct genetic typing on the locus of GCKR gene rs1260326.The two groups were compared in the genotype of GCKR gene rs1260326 locus and the distribution frequency of GCKR gene rs1260326 allele.Logistic regression analysis was conducted to analyze the relationship between the polymorphism of GCKR gene rs1260326 locus and T2DM.Results The T2DM was higher(P<0.05) than the control group in BMI,WHR and WC.The two groups were not significantly different(P>0.05) in SBP and DBP.The T2DM group was higher(P<0.05) in TC and FPG and lower(P<0.05) in HDL-C and LDL-C than the control group.The two group were not significantly different(P>0.05) in TG.The frequency distributions of the genotype of GCKR gene rs1260326 locus of the two groups accorded with the Hardy-Weinberg equilibrium,which indicated that the samples of the two groups were representative of the population.The T2DM group was not significantly different(P>0.05) in the genotype of rs1260326 locus and rs1260326 locus allele from the control group.The Logistic regression analysis showed that the recessive genetic model of GCKR gene rs1260326 was the influencing factor for T2DM(P<0.05).The multivariate Logistic regression analysis showed that the variables that entered the main effect model included gender,WHR,TC,TG,HDL-C and the recessive genetic model of GCKR gene rs1260326(P<0.05).Conclusion Among Uygur in Xinjiang,the polymorphism of GCKR gene rs1260326 is correlated with T2DM,and TT genotype may be the protective factor for the occurrence of T2DM.
Diabetes mellitus,type 2;Polymorphism,single nucleotide;GCKR gene;Uygur nationality
國家重點基礎(chǔ)研究發(fā)展計劃(973計劃)(2012CB722403);新疆重大疾病醫(yī)學(xué)重點實驗室開放課題(SKLIB-XJMDR-2014-Y4);新疆醫(yī)科大學(xué)第一附屬醫(yī)院科研基金(2013ZRQN18)
830054新疆烏魯木齊市,新疆醫(yī)科大學(xué)第一附屬醫(yī)院新疆代謝性疾病重點實驗室(王黎,馬琦,姚華),臨床醫(yī)學(xué)研究院(房彬彬),內(nèi)分泌科(朱筠),體檢與健康管理中心(王淑霞),臨床檢驗中心(張朝霞)
姚華,830054新疆烏魯木齊市,新疆醫(yī)科大學(xué)第一附屬醫(yī)院新疆代謝性疾病重點實驗室;
E-mail:yaohua01@sina.com
R 87.1
A
10.3969/j.issn.1007-9572.2015.21.005
2014-12-17;
2015-05-05)
注:王黎與馬琦同為第一作者